Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
29 Jan 2020
Historique:
received: 31 12 2019
revised: 20 01 2020
accepted: 27 01 2020
entrez: 5 2 2020
pubmed: 6 2 2020
medline: 18 11 2020
Statut: epublish

Résumé

Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing. Janus kinase (JAK) inhibition with tofacitinib has been demonstrated to act as a potent anti-inflammatory therapeutic agent in the treatment of RA, but its impact on the fundamental processes of bone regeneration is currently controversially discussed and at least in part elusive. Therefore, in this study, we aimed to examine the effects of tofacitinib on processes of bone healing focusing on recruitment of human mesenchymal stromal cells (hMSCs) into the inflammatory microenvironment of the fracture gap, chondrogenesis, osteogenesis and osteoclastogenesis. We performed our analyses under conditions of reduced oxygen availability in order to mimic the in vivo situation of the fracture gap most optimal. We demonstrate that tofacitinib dose-dependently promotes the recruitment of hMSCs under hypoxia but inhibits recruitment of hMSCs under normoxia. With regard to the chondrogenic differentiation of hMSCs, we demonstrate that tofacitinib does not inhibit survival at therapeutically relevant doses of 10-100 nM. Moreover, tofacitinib dose-dependently enhances osteogenic differentiation of hMSCs and reduces osteoclast differentiation and activity. We conclude from our data that tofacitinib may influence bone healing by promotion of hMSC recruitment into the hypoxic microenvironment of the fracture gap but does not interfere with the cartilaginous phase of the soft callus phase of fracture healing process. We assume that tofacitinib may promote bone formation and reduce bone resorption, which could in part explain the positive impact of tofacitinib on bone erosions in RA. Thus, we hypothesize that it will be unnecessary to stop this medication in case of fracture and suggest that positive effects on osteoporosis are likely.

Identifiants

pubmed: 32013232
pii: ijms21030865
doi: 10.3390/ijms21030865
pmc: PMC7037633
pii:
doi:

Substances chimiques

Collagen Type I 0
Collagen Type I, alpha 1 Chain 0
Core Binding Factor Alpha 1 Subunit 0
Janus Kinase Inhibitors 0
Piperidines 0
Pyrimidines 0
Pyrroles 0
RUNX2 protein, human 0
tofacitinib 87LA6FU830
Janus Kinases EC 2.7.10.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Pfizer Pharmaceuticals
ID : WI220797

Références

Immunol Res. 2016 Dec;64(5-6):1195-1206
pubmed: 27629117
Cytokine. 2004 Jun 7;26(5):223-30
pubmed: 15157900
PLoS One. 2017 Jul 14;12(7):e0181126
pubmed: 28708884
Immunol Res. 2011 Oct;51(1):116-22
pubmed: 21720875
Arthritis Res Ther. 2019 Oct 21;21(1):214
pubmed: 31639034
Joint Bone Spine. 2017 Jul;84(4):411-416
pubmed: 27777170
Curr Opin Rheumatol. 2016 May;28(3):282-8
pubmed: 27027814
Lancet. 2013 Feb 9;381(9865):451-60
pubmed: 23294500
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Clin Rheumatol. 2018 Sep;37(9):2367-2372
pubmed: 29948347
Cell Tissue Res. 2012 Mar;347(3):567-73
pubmed: 21789579
Injury. 2007 Dec;38(12):1401-4
pubmed: 18045600
Ultrastruct Pathol. 2005 Mar-Apr;29(2):107-20
pubmed: 16028667
Clin Exp Rheumatol. 2009 Jan-Feb;27(1):99-107
pubmed: 19327236
Int J Mol Sci. 2017 Mar 08;18(3):
pubmed: 28282868
Tissue Eng Part B Rev. 2010 Aug;16(4):427-34
pubmed: 20196645
Arthritis Rheum. 2012 Nov;64(11):3531-42
pubmed: 22899318
Hepatogastroenterology. 2006 Sep-Oct;53(71):730-5
pubmed: 17086878
N Engl J Med. 2012 Aug 9;367(6):508-19
pubmed: 22873531
Clin Exp Rheumatol. 2015 Jan-Feb;33(1):115-21
pubmed: 25535750
Trends Immunol. 2006 Jul;27(7):303-7
pubmed: 16731040
Arthritis Rheumatol. 2014 Jan;66(1):121-9
pubmed: 24431283
N Engl J Med. 2012 Aug 9;367(6):495-507
pubmed: 22873530
J Immunol. 2010 May 1;184(9):5298-307
pubmed: 20363976
Curr Opin Pharmacol. 2018 Jun;40:110-119
pubmed: 29702364
Arthritis Res Ther. 2008;10(1):R14
pubmed: 18234077
Ann Rheum Dis. 2016 Jul;75(7):1293-301
pubmed: 26275429
Horm Metab Res. 2016 Nov;48(11):764-770
pubmed: 27728929
Pharmacotherapy. 2005 Nov;25(11):1566-91
pubmed: 16232020
J Clin Densitom. 2020 Jan - Mar;23(1):37-43
pubmed: 30773275
J Bone Miner Metab. 2014 Jul;32(4):378-92
pubmed: 24122251
Acta Endocrinol (Buchar). 2019 Apr-Jun;15(2):231-236
pubmed: 31508182
JAKSTAT. 2013 Jul 1;2(3):e23930
pubmed: 24069548
J Bone Miner Res. 2014 Nov;29(11):2307-22
pubmed: 25264148
Clin Interv Aging. 2018 Aug 24;13:1465-1474
pubmed: 30197508
Steroids. 2010 Mar;75(3):282-6
pubmed: 20096296
Int J Biochem Cell Biol. 2010 Nov;42(11):1823-30
pubmed: 20691278
Clin Orthop Relat Res. 1999 Sep;(366):8-21
pubmed: 10627713
Clin Orthop Relat Res. 2011 Nov;469(11):3118-26
pubmed: 21409457
J Bone Miner Res. 2016 Feb;31(2):403-15
pubmed: 26255791
Eur Cell Mater. 2017 Oct 17;34:202-216
pubmed: 29039630
Immun Ageing. 2006 Nov 29;3:10
pubmed: 17134511
PLoS One. 2012;7(9):e46483
pubmed: 23029528
Z Rheumatol. 2019 Aug;78(6):529-539
pubmed: 31297605
J Cell Physiol. 2010 Apr;223(1):123-33
pubmed: 20039267
Ann Rheum Dis. 2016 Jun;75(6):1024-33
pubmed: 27002108
Mod Rheumatol. 2017 Mar;27(2):193-197
pubmed: 28051887

Auteurs

Timo Gaber (T)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Antonia Clara Katharina Brinkman (ACK)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Justyna Pienczikowski (J)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Karoline Diesing (K)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Alexandra Damerau (A)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Moritz Pfeiffenberger (M)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Annemarie Lang (A)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Sarah Ohrndorf (S)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.

Gerd-Rüdiger Burmester (GR)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Frank Buttgereit (F)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.

Paula Hoff (P)

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, 10117 Berlin, Germany.
German Rheumatism Research Centre (DRFZ) Berlin, a Leibniz Institute, 10117 Berlin, Germany.
Endokrinologikum Berlin, 10117 Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH